Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy
Abhinav V. Reddy, Colin S. Hill, Shuchi Sehgal, Lei Zheng, Jin He, Daniel A. Laheru, Ana De Jesus-Acosta, Joseph M. Herman, Jeffrey Meyer, Amol K. Narang
Radiat Oncol J. 2022;40(2):111-119. Published online 2022 May 20 DOI: https://doi.org/10.3857/roj.2021.01060
Citations to this article as recorded by 
Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer
Ji Hye Min, Jeong Il Yu, Seong Hyun Kim, Young Kon Kim, Kangpyo Kim, Hee Chul Park, Joon Oh Park, Jung Yong Hong, Kyu Taek Lee, Kwang Hyuck Lee, Jong Kyun Lee, Joo Kyung Park, Jin Ho Choi, Jin Seok Heo, In Woong Han, Hongbeom Kim, Sang Hyun Shin, So Jung
Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Inflammatory markers in predicting survival in pancreatic cancer: A Systematic review and Meta-Analysis
Rinrada Worapongpaiboon, Noppachai Siranart, Patavee Pajareya, Somkiat Phutinart
Pancreatology.2025;[Epub] CrossRef
Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials
Abhinav Shenoy, Amar Yousif, Muhammad Delwar Hussain
Cancers.2025; 17(8): 1319. CrossRef
Cellular Components Contributing to the Development of Venous Thrombosis in Patients with Pancreatic Cancer
Ruth Anne Laura Willems, Charlotte Biesmans, Elena Campello, Paolo Simioni, Bas de Laat, Judith de Vos-Geelen, Mark Roest, Hugo ten Cate
Seminars in Thrombosis and Hemostasis.2024; 50(03): 429. CrossRef
Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy
Qihang Wu, Han Mao, Zhengting Jiang, Dong Tang
Immunology.2024; 172(3): 343. CrossRef
Progress in the development of vaccines for pancreatic adenocarcinoma
Singer Mahmoud, Elsayed Ahmed M, Husseiny Mohamed I
Annals of Pancreatic Disorders and Treatment.2024; 6(1): 001. CrossRef
Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma
Shi-Qiong Zhou, Peng Wan, Sen Zhang, Yuan Ren, Hong-Tao Li, Qing-Hua Ke
World Journal of Clinical Oncology.2024; 15(7): 859. CrossRef
Optimization of combined chemoradiotherapy and immunotherapy for locally advanced esophageal cancer
Ke Zhang, Zongchang Nie, Jun Wang, Qingsong Pang, Ping Wang, Cihui Yan, Zhihao Lu, Wencheng Zhang
The Innovation Medicine.2024; 2(4): 100095. CrossRef
Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?
Sofian Benkhaled, Cedric Peters, Nicolas Jullian, Tatjana Arsenijevic, Julie Navez, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem, Christelle Bouchart
Cancers.2023; 15(3): 768. CrossRef
The current understanding of the immune landscape relative to radiotherapy across tumor types
Chrysanthi Iliadi, Laurine Verset, Christelle Bouchart, Philippe Martinive, Dirk Van Gestel, Mohammad Krayem
Frontiers in Immunology.2023;[Epub] CrossRef
Emerging evidence for adapting radiotherapy to immunotherapy
Lorenzo Galluzzi, Molykutty J. Aryankalayil, C. Norman Coleman, Silvia C. Formenti
Nature Reviews Clinical Oncology.2023; 20(8): 543. CrossRef
Stereotactic body radiation therapy for pancreatic cancer: a potential ally in the era of immunotherapy?
Jin-hong Park
Radiation Oncology Journal.2022; 40(3): 169. CrossRef